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AmphipathicThe increase in multidrug resistant bacteria has sparked an interest in the development of novel antibiotics.
Antimicrobial peptides that operate by crossing the cell membrane may also have the potential to deliver
drugs to intracellular targets. Buforin 2 (BF2) is an antimicrobial peptide that shares sequence identity
with a fragment of histone subunit H2A and whose bactericidal mechanism depends on membrane translo-
cation and DNA binding. Previously, novel histone-derived antimicrobial peptides (HDAPs) were designed
based on properties of BF2, and DesHDAP1 and DesHDAP3 showed signiﬁcant antibacterial activity. In this
study, their DNA binding, permeabilization, and translocation abilities were assessed independently and
compared to antibacterial activity to determine whether they share a mechanism with BF2. To investigate
the importance of proline in determining the peptides’ mechanisms of action, proline to alanine mutants of
the novel peptides were generated. DesHDAP1, which shows signiﬁcant similarities to BF2 in terms of sec-
ondary structure, translocates effectively across lipid vesicle and bacterial membranes, while the DesHDAP1
proline mutant shows reduced translocation abilities and antimicrobial potency. In contrast, both DesHDAP3
and its proline mutant translocate poorly, though the DesHDAP3 proline mutant is more potent. Our ﬁndings
suggest that a proline hinge can promote membrane translocation in some peptides, but that the extent of its
effect on permeabilization depends on the peptide's amphipathic properties. Our results also highlight the
different antimicrobial mechanisms exhibited by histone-derived peptides and suggest that histones may
serve as a source of novel antimicrobial peptides with varied properties.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Growing concern over the rise of multidrug resistant bacterial
strains has led to increased interest in the discovery of novel antibi-
otics. Antimicrobial peptides (AMPs) are a class of short amino acid
sequences produced by animals, plants, and even bacteria themselves
to ward off infection. Most naturally occurring AMPs contain 10–50
amino acid residues, multiple positive charges, and several hydropho-
bic residues. Many AMPs exhibit relatively non-speciﬁc bactericidal
activity against both gram-positive and gram-negative species and
selectively kill prokaryotic rather than eukaryotic cells [1].
AMPs are often truncated versions of larger proteins within the
cell, many of which also show some antibacterial activity [2]. For ex-
ample, although histone core particles are generally located within
the cell nucleus as part of condensed chromatin, recent studies have
isolated cytoplasmic and secreted histone proteins with antimicrobial
activity from a wide range of organisms and tissues, such as mollusks
[3], ﬁsh [4], amphibians [5], and the human gastrointestinal tract [6].ent of Chemistry, 106 Central
fax: +1 781 283 3642.
).
rights reserved.The antimicrobial role of histones has been discussed further in re-
cent reviews [7,8]. All four histone core subunits as well as H1 are ca-
pable of crossing cell membranes as well as sometimes mediating the
crossing of other small molecules [9,10]. Recent work has further in-
vestigated the antibacterial mechanism of histones H3 and H4 [11].
Additionally, several naturally occurring AMPs share sequence identi-
ty with portions of various histone subunits, implying that both
whole and fragmented histone proteins may possess antibacterial
properties [7,8].
The best-studied histone-derived antimicrobial peptide (HDAP) is
buforin II (BF2), which is identical to a part of histone subunit H2A.
BF2 is noteworthy because it uses an uncommon mechanismwherein
it kills bacteria without causing cell lysis and is able to cross bacterial
membranes [12] and enter lipid vesicles [13]. AMPs that operate
through this type of cell-penetrating mechanism are of particular in-
terest to the medical and scientiﬁc communities for both their poten-
tial to assist in targeting drug molecules to the cytoplasm and for their
bactericidal properties [14]. After entering cells, BF2 is believed to kill
microbes through interactions with nucleic acids [12,15].
Several studies have focused on the importance of BF2's sole proline
residue on its function [13,16,17]. This proline provides a hinge in the
helical structure of the peptide and plays a critical role in promoting
peptide translocation. BF2 adopts a partially α-helical conformation in
870 K.E. Pavia et al. / Biochimica et Biophysica Acta 1818 (2012) 869–876the presence of anionic lipid vesicles [13]. Proline cannot form the hy-
drogen bonds necessary to stabilize an α-helix, thus the presence of
proline in the generally helical structure of BF2 introduces ﬂexibility
and distorts the N-terminal region of the helix, which in turn increases
the helix's amphipathic nature [18]. The BF2 P11A mutant has a longer
undistorted helical region but shows signiﬁcantly decreased transloca-
tion across lipid vesicle membranes and reduced antibacterial potency
[13]. Subsequent work has shown that the proline in BF2 is in an ideal
position for translocation, as moving it one turn towards either the
N- or C-terminus signiﬁcantly reduces the translocation ability of the
peptide [17].
Tsao et al. previously described three novel designed histone-
derived antimicrobial peptides (DesHDAPs 1–3) [19]. These peptides
were designed to incorporate several characteristics of BF2. All three
peptides share exact sequence identity to a fragment of a histone
subunit predicted to bind to DNA; DesHDAP1 is derived from H2A,
DesHDAP2 from H3, and DesHDAP3 from H4. The peptides also all
possess multiple positive charges and one proline residue that dis-
rupts a C-terminal helical region.
Although these peptides were designed based on properties of
BF2, it is unclear whether these characteristics imbued all the
designed peptides with a BF2-like mechanism. DesHDAPs 1 and 3
show signiﬁcantly stronger antibacterial activity against both gram-
negative and gram-positive bacteria than DesHDAP2, and are thus
the primary focus of this study. However, the growth curves of bacte-
ria exposed to DesHDAPs 1 and 3 show dissimilar shapes, implying
possible mechanistic differences [19]. In order to characterize these
potential differences, we have measured the translocation ability,
membrane permeabilization, and DNA binding of these two peptides.
The results clearly show that the two peptides utilize divergent
mechanisms, with DesHDAP1 translocating much more readily across
membranes than DesHDAP3. Moreover, proline mutations in the two
peptides exhibit opposite effects on antimicrobial activity and lead to
distinct changes in membrane translocation and permeabilization
properties.
2. Materials and methods
2.1. Peptides
Buforin II F10W, DesHDAP1, DesHDAP2, and DesHDAP3 (Table 1)
were synthesized and puriﬁed by GenScript (Piscataway, NJ) to >95%
purity. Proline to alanine mutant versions of each peptide were also
purchased at >95% purity. Wild type and mutant peptides with an
N-terminal biotin group were also obtained at >95% purity. All pep-
tides had an unmodiﬁed C-terminus with a free carboxylic acid, and
peptides that did not have an N-terminal biotin group had a free
amine group at the N-terminus with no other modiﬁcation. Peptides
were dissolved in nanopure H2O and stored at −20 °C. Peptide con-
centrations were determined from the absorbance signals of native
tryptophan residues. Absorbance was measured with a BioradTable 1
Sequences of buforin II, DesHDAP1, DesHDAP2, and DesHDAP3, with proline or muta-
tion shown in bold.
Peptide Histone subunit
source
Amino acid sequence # of amino
acids
Buforin II (BF2) H2A TRSSRAGLQWPVGRVHRLLRK 21
DesHDAP1 H2A ARDNKKTRIWPRHLQLAVRN 20
DesHDPA2 H3 HRYRPGTVALREIRRYQKST 20
DesHDAP3 H4 KVLRDNIQGWTKPAIRRLARRG 22
DesHDAP1 P11A
mutant
H2A ARDNKKTRIWARHLQLAVRN 20
DesHDAP2 P5A
mutant
H3 HRYRAGTVALREIRRYQKST 20
DesHDAP3 P13A
mutant
H4 KVLRDNIQGWTKAAIRRLARRG 22SmartSpec Plus spectrophotometer (Philadelphia, PA) or a Thermo
Scientiﬁc Nanodrop 2000 (Wilmington, DE).
2.2. Circular dichroism measurements
Circular dichroism spectra were collected from 190 to 250 nm
using an Olis DSM 20 circular dichroism spectrometer (Bogart, GA)
in Starna 1 mm path-length quartz cuvettes (Atascadero, CA). All
peptides were at a concentration of 25 μM. Spectra were collected in
a 1:1 triﬂuoroethanol (Arcos Organics, NJ):phosphate buffer (10 mM
Na3PO4, 45 mM NaCl, 1 mM EDTA, pH 7.4) solution. Reported spectra
are the average of 10 scans collected at 25 °C with an integration time
of 2.0 s.
2.3. Radial diffusion assay for antibacterial potency
The radial diffusion assay was performed as described elsewhere
[20] on two gram-negative bacterial strains (Escherichia coli ATCC
#25922, Serratia marcescens Carolina #155450A) and three gram-
positive bacterial strains (Enterococcus faecalis ATCC #29212, Staphy-
lococcus aureus Carolina #155554A, Bacillus subtilis ATCC #6051).
Cells picked from frozen bacterial stocks were incubated overnight
at 37 °C in trypticase soy broth (30% TSB w/v) (Sigma Aldrich) to
log phase. The overnight culture was diluted 1:1000 in fresh TSB
and grown for 2.5 h. Bacteria were pelleted via centrifugation at ap-
proximately 880×g for 10 min at 4 °C and washed with 10 mM phos-
phate buffer (10 mM Na3PO4, pH 7.4). 10 mL of molten agarose gel
(10 mM Na3PO4, 1% TSB v/v, 1% agarose w/v, pH 7.4) was inoculated
with 4×106 CFU of bacteria in phosphate buffer and allowed to solid-
ify on a petri dish. 2.5 μL of 3×10−4 M peptide solution was added to
1-mm wells in the underlay gel and incubated at 37 °C for 3 h. 10 mL
of overlay gel (30% w/v TSB , 1% w/v agarose) was poured over the
underlay gel and incubated overnight at 37 °C. The area of bacterial
clearing was measured at 7× magniﬁcation.
2.4. Lipid vesicle translocation assay
Lipid vesicles were prepared essentially as described in Torchilin
and Weissig [21]. Phospholipids dissolved in chloroform were pur-
chased from Avanti Polar Lipids (Alabaster, AL). Chloroform was
evaporated from a 50:45:5 mixture of phosphatidylcholine (POPC),
phosphatidylglycerol (POPG), and 5-dimethylaminonaphthalene-1-
sulfonyl phosphatidylethanolamine (DNS-POPE) using a nitrogen
gas stream. Following overnight desiccation, anhydrous lipid cakes
were rehydrated in 10 mM HEPES buffer (10 mM HEPES, 45 mM
NaCl, 1 mM EDTA, pH 7.4) containing either 0.2 mM porcine trypsin
(Sigma-Aldrich) or 0.2 mM porcine trypsin and 2.0 mM Bowman–
Birk trypsin inhibitor (Sigma Aldrich) and subjected to ﬁve freeze–
thaw cycles. Vesicles were extruded 21 times through a nuclepore
track etchmembrane with 0.1 μmpores (Whatman, United Kingdom)
in an Avanti Polar Lipids extruder to ensure uniform vesicle size. Ves-
icle concentration was measured in triplicate as a function of total
phosphorus content in solution (http://www.avantilipids.com/index.
php?Option=com_content&view=article&id=1686&Itemid=405).
Translocation ability was measured generally as described by
Kobayashi et al. [13]. Trypsin located outside of experimental,
trypsin-containing vesicles was inhibited by the addition of Bow-
man–Birk trypsin inhibitor such that the ﬁnal inhibitor concentration
was 10× that of the trypsin. Fluorescence emission at 525 nm was
then monitored for 25 min following peptide exposure to vesicles
with an excitation wavelength of 280 nm. For all samples, peptides
were at a concentration of 3 μM and vesicles were at a concentration
of 250 μM. Fluorescent emission was also monitored under the same
conditions described above using vesicles containing 0.2 mM trypsin
and 2 mM Bowman–Birk inhibitor to control for changes in ﬂuores-
cent signal unrelated to translocation. The ﬁnal average ﬂuorescence
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lated by dividing the average of the ﬂuorescence values collected dur-
ing the last minute of the experiment by the ﬂuorescence at 15 s after
combining peptide and vesicle samples (Fo). The F0 was taken at 15 s
to reduce artifacts in the ﬂuorescence signal that can occur immedi-
ately after mixing in the sample. A quantitative translocation ratio
(TR) was calculated for each peptide by dividing the Ffavg for the con-
trol vesicles by the Ffavg for the experimental vesicles.
2.5. Confocal microscopy
Peptide translocation into E. coli cells (ATCC #25922) was visual-
ized essentially as described by Park et al. [22]. Brieﬂy, an overnight
culture of Top10 E. coli (Invitrogen) was diluted 1:100 in TSB media
and allowed to grow to mid-logarithmic phase. Bacteria were pelleted
via centrifugation at approximately 880×g and resuspended in
10 mM phosphate buffer, pH 7.4. Bacterial cells at a concentration of
107 CFU/mL were incubated with 16 μg/mL biotinylated peptide for
30 min at 37 °C. Cells were then placed on poly-L-lysine coated glass
slides and exposed to Triton-X with a ﬁnal concentration of 0.066%
Triton-X/phosphate buffer for 1–2 min. Biotinylated peptides were
visualized following the addition of a streptavidin-AlexaFluor488
conjugate (Invitrogen) to a ﬁnal concentration of 5 μg/mL. Cells
were observed using a Leica TCS-SP1 confocal microscope with exci-
tation at 488 nm. All images represent the average of at least four
scans.
2.6. DNA binding
Peptide binding to nucleic acids was measured using a ﬂuores-
cence intercalator displacement assay [23]. The ﬂuorescence intensity
of 0.55 μM Thiazole Orange in STE buffer (10 mM Tris, 50 mM NaCl,
1 mM EDTA, pH 8.0) was measured using a Varian Cary Eclipse ﬂuo-
rescence spectrophotometer (excitation wavelength: 509 nm; emis-
sion wavelength: 527 nm) and normalized to 0% relative
ﬂuorescence. dsDNA (IDT, Coralville, IA) used in previous studies of
BF2 DNA binding [15] (AAATACACTTTTGGT) was prepared in STE
buffer and added to the thiazole orange solution to a ﬁnal concentra-
tion of 1.1 μM base pairs. The solution was allowed to equilibrate for
several minutes before the ﬂuorescence was measured. The solution
was then titrated with a 78 μM peptide solution, allowing 5 min
equilibration prior to measurement of ﬂuorescence after each peptide
addition. The peptide concentration at which ﬂuorescence intensity
was decreased to half was extrapolated, and usually fell within a con-
centration of 1–10 mM. Reported measurements are from at least
three independent experiments for each peptide.
2.7. Membrane permeabilization
Bacteria picked from a frozen stock were allowed to grow over-
night at 37°C in TSB media (30% w/v TSB) (Sigma). The overnight cul-
ture was diluted 1:1000 into fresh TSB and allowed to grow to an
optical density of between 0.2 and 1.0. Bacteria were pelleted by cen-
trifugation at 880×g, resuspended in sterile phosphate buffer
(100 mM Na3PO4 in H2O, pH 7.4), pelleted again, and ﬁnally sus-
pended in sterile phosphate buffer to an optical density of 0.5. Propi-
dium iodide (PI) was added at a concentration of 20 μg/mL and the
system allowed to equilibrate. PI complexed with intracellular DNA
was excited at 535 nm and ﬂuorescence measured at 617 nm on a
Varian Cary Eclipse ﬂuorescence spectrophotometer. After the
untreated cells had equilibrated, peptide was added to a concentra-
tion of 2 μM and ﬂuorescence was monitored. The increase in ﬂuores-
cence due to presence of peptide was determined by comparing the
ﬂuorescence 5 min after peptide addition to the averaged value for
the ﬂuorescence in the minute prior to peptide addition.3. Results and discussion
3.1. Designed HDAPs do not share a mechanism of action
BF2's antimicrobial potency is dependent on its ability to cross bac-
terial and lipid vesicle membranes [13,22]. The absorbance proﬁles of
bacteria exposed to DesHDAP1 resemble those of BF2, suggesting that
it too might use a translocation-based antimicrobial mechanism [19].
In contrast, the absorbance proﬁle of cells exposed to DesHDAP3
shows a dramatic drop signifying cell lysis, which raises questions
about whether it shares a mechanism with BF2. The designed pep-
tides’ translocation abilities into bacteria were assessed qualitatively
using confocal laser microscopy. In these experiments, E. coliwere ex-
posed to biotinylated DesHDAP1 and DesHDAP3 and visualized with a
streptativdin-AlexaFluor488 conjugate. Like BF2, DesHDAP1 generally
appeared to be internalized by bacteria that showed ﬂuorescence
(Fig. 1A). In contrast, DesHDAP3 showed little entry into cells and
was primarily localized to bacterial cell membranes (Fig. 1B).
The designed HDAPs’ translocation abilities were determined
more quantitatively using the vesicle based translocation assay previ-
ously used by Matsuzaki and co-workers to characterize the function
of BF2 [16]. In this assay, the native tryptophan residues in each pep-
tide act as FRET donors when associated with 50:45:5 POPC:POPG:
DNS-POPE lipid vesicles, producing a ﬂuorescent signal. As peptides
cross the lipid bilayer, they are digested by trypsin trapped within
the vesicle, leading to a loss of FRET signal. To control for loss of
FRET signal due to incomplete inhibition of the trypsin outside vesi-
cles or other factors unrelated to translocation ability, the FRET signal
between the peptide and vesicles encapsulating both trypsin and
trypsin inhibitor was also monitored. A signiﬁcant decrease in FRET
signal as compared to this control is therefore indicative of a peptide
that readily translocates across membranes.
The drop in ﬂuorescence observed for DesHDAP1 (Fig. 2B) is sig-
niﬁcantly greater than the drop observed in its control scenario. In
our experience, the relative ﬂuorescence drop observed for DesH-
DAP1 is even larger than that observed for BF2 in our vesicle samples
(Fig. 2A). Together with the observed translocation into E. coli cells,
this suggests that DesHDAP1, like BF2, is a cell-penetrating AMP
that spontaneously crosses lipid membranes.
In order to quantify the translocation, we averaged the ratio of the
control and experimental signals over three independent experi-
ments. Our quantitative translocation ratio for BF2 is somewhat
lower than the apparent value in data shown by Kobayashi et al.
[13] This difference was likely due to the different sources of lipid
(e.g. egg lipids versus chemically synthesized POPC and POPG used
in this study) and different sources of trypsin and trypsin inhibitor.
However, our quantitative translocation ratios for both BF2 and
DesHDAP1 are indicative of membrane translocation. In contrast,
DesHDAP3 showed a much smaller decrease in ﬂuorescence when
compared to controls (Fig. 2C), indicating that it did not exhibit ap-
preciable translocation (Table 2).
After translocating across the cell membrane, cell-penetrating
AMPs must be able to reach and interact with their intracellular tar-
get(s). In BF2, DNA binding is correlated with overall potency, indi-
cating that DNA binding is indeed critical to the bactericidal
mechanism [15]. The DNA binding strength of DesHDAPs 1 and 3
was assessed by measuring the peptide concentration required to dis-
place thiazole orange from double stranded DNA (Fig. 3, Table 3). In
this assay, DesHDAP1 bound DNA somewhat more weakly than BF2,
which may partially explain why BF2 is more potent against some
bacterial strains than DesHDAP1 [19]. In contrast, DesHDAP3 bound
to DNA with approximately the same afﬁnity as BF2. However, since
DesHDAP3 is unable to cross membranes effectively, its enhanced
DNA binding is clearly less relevant for its antimicrobial activity.
Moreover, the differences in DNA binding between these peptides
are relatively small and therefore assumedly less important in
Fig. 1. Translocation of DesHDAP1 (A), DesHDAP3 (B), DesHDAP1 P11A (C–D), and DesHDAP 3 P13A (E) into E. coli. 107 CFU/mL bacteria were incubated with biotinylated peptides
(16 μg/mL). Peptides localization was assessed following treatment with a streptavidin-AlexaFluor488 conjugate and visualized on a Leica TCS-SP1 confocal microscope with exci-
tation at 488 nm. A 2 μm scale bar is provided in the images.
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and permeabilization abilities of these peptides.
If DesHDAP3 does not function through effective translocation
across lipid membranes, its antimicrobial activity may arise from an
ability to permeabilize membranes. To test this possibility, we mea-
sured membrane permeabilization with a propidium iodide based
assay. Although these peptides do have some afﬁnity for DNA, appre-
ciable competition between peptide and PI binding should not occur
because of the high DNA binding constant of PI and the 750-fold
higher concentration of PI compared to peptide in these experiments.
Both designed peptides were relatively unable to permeabilize E. coli
membranes (Fig. 4, Table 4), showing a lower ﬂuorescence from0.6
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Fig. 2. Translocation of BF2 (A),DesHDAP1 (B), DesHDAP3 (C), DesHDAP1 P11A (D), and Des
vesicles (250 μM) containing trypsin. The FRET signal at 525 nm (black) is plotted as the ﬂuo
In control traces (gray), peptides were exposed to vesicles containing both trypsin and trypPI entering the cell than observed for BF2. The observations that
DesHDAP3 is less effective at membrane translocation and no better
at causing membrane permeabilization than DesHDAP1 are consis-
tent with the relatively lower antibacterial activity of the wild type
DesHDAP3 peptide.
3.2. The proline hinge plays a different role in the function of DesHDAP1
and DesHDAP3
DNA binding and translocation studies indicate that DesHDAP1
likely uses a mechanism similar to the one employed by BF2, while
DesHDAP3 is signiﬁcantly less able to translocate across membranes.15 20 25
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HDAP3 P13A (E) across lipid vesicle membranes. Peptides (3 μM) were exposed to lipid
rescent signal throughout the experiment relative to the initial ﬂuorescent signal (F/Fo).
sin inhibitor.
Table 2
Translocation of DesHDAP1, DesHDAP3 and their proline to alanine mutants into lipid
vesicles. The reported translocation ratios represent the ratio of the retention of ﬂuo-
rescence after 25 min of the translocation control to that of the experimental condi-
tions. Uncertainty is reported as a standard deviation.
Peptide Translocation ratio
DesHDAP1 1.13±0.08
DesHDAP1 P11A 1.11±0.01
DesHDAP3 0.97±0.04
DesHDAP3 P13A 0.982±0.005
Buforin II 1.07±0.06
Table 3
DNA binding of the novel HDAPs measured by ﬂuorescent intercalator displacement.
The concentration of peptide required to decrease the ﬂuorescence of thiazole orange
by 50% (C50) was calculated by monitoring the decrease in ﬂuorescence. Relative
binding is normalized compared to BF2. Uncertainty is reported as a standard
deviation.
Peptide C50 (μM) Relative C50
BF2 8.0±1 1
DesHDAP1 10.2±0.5 1.28
DesHDAP3 8.7±1 1.09
BF2
magainin
DesHDAP1 
DesHDAP1 P11A
DesHDAP3
DesHDAP3 P13A
873K.E. Pavia et al. / Biochimica et Biophysica Acta 1818 (2012) 869–876Both BF2's translocation ability and ultimately its bactericidal activi-
ty are closely tied to the presence of a helix-breaking proline hinge in
its structure [13,22], as mutating this proline to alanine signiﬁcantly
decreases the antimicrobial potency and translocation ability of
BF2 while increasing its membrane permeabilization [13,16]. Both
DesHDAP1 and DesHDAP3 were designed to have an analogous pro-
line hinge, so proline to alanine mutants of DesHDAPs 1 and 3 were
generated to assess the role that the proline hinge plays in determin-
ing the mechanism and biological activity of these novel HDAPs.
CD spectra of the peptides in a solution of 50% triﬂuoroethanol con-
ﬁrm the structural changes that result from the proline to alaninemuta-
tions (Fig. 5). As observed previously [19], the wild type DesHDAP1
peptide has a CD spectrum very similar to that of BF2, implying that it
likely shares a partially helical structure with BF2, whereas wild type
DesHDAP3 has signiﬁcantly greater helical character. As expected, the
proline mutation increases the α-helical structure of both peptides.
However, the effect is more dramatic for the DesHDAP1 peptide,
which was originally less helical.
Antibacterial potency of the DesHDAP1 and DesHDAP3 peptides and
their proline mutants was measured using a radial diffusion assay
(Fig. 6). As seen in previous studies, DesHDAP1 showed antibacterial
activity similar to that of BF2, while DesHDAP3 had somewhat lower ac-
tivity [19].We note that the activity of the DesHDAP1 sample used in this
work appeared somewhat higher against some strains than observed
previously, but general trends in activity against differing strains were
consistent [19]. Like BF2 P11A, DesHDAP1 P11A showed reduced activity
against all bacterial species tested (Fig. 6A). In contrast, removing the pro-
line hinge improved the bactericidal activity of DesHDAP3, as DesHDAP3
P13A showed greater activity against all bacterial strains than the parent
peptide (Fig. 6C). In fact, the potency of DesHDAP3 P13A is comparable to
that of DesHDAP1 and BF2.
Because the proline to alanine mutation dramatically increased
DesHDAP3's antibacterial potency, we decided to determine whether0.4
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Fig. 3. Representative titration data from ﬂuorescent intercalator assays measuring the
DNA binding of BF2, DesHDAP1 and DesHDAP3.a similar mutation would improve its activity of the relatively weaker
peptide DesHDAP2. In fact, DesHDAP2 P5A did show greater bacteri-
cidal activity than wild type DesHDAP2 (Fig. 6B), and may therefore
share some mechanistic or structural similarities with DesHDAP3.
However, DesHDAP2 P5A remained a signiﬁcantly weaker antimicro-
bial agent than BF2, DesHDAP1, and DesHDAP3 P13A, and was there-
fore not characterized any further in this study.
In order to explain these divergent trends in activity for DesHDAPs1
and 3, we characterized how the proline mutations altered the mem-
brane translocation and permeabilization of the two peptides. The
vesicle-based translocation assay suggested a potential decrease in
DesHDAP1 P11A's translocation abilities compared with wildtype pep-
tide (Table 2, Fig. 2D), although this decrease was within the experi-
mental error of our method. Decreased translocation also arose in
microscopy data, where some bacteria exposed to DesHDAP1 P11A dis-
played peptide internalization while others within the same slide
showed localization of the peptide to themembrane (Fig. 1C–D). Overall
these observations are consistent with the proline mutation somewhat
reducing, but not eliminating, DesHDAP1 translocation. This reduction
in translocation efﬁciencymay explain the decrease inDesHDAP1 bacte-
ricidal activity and suggests that the proline hinge plays a role in peptide
translocation for both BF2 andDesHDAP1. Like thewild typeDesHDAP3,
DesHDAP3 P13A showedminimal translocation in both lipid vesicle and
bacterial studies (Table 2, Figs. 1E, 2E). This suggests that the proline
hinge aids in translocation for some HDAPs, but that the proline hinge
alone does not necessarily confer translocation abilities.
To assess whether any of the peptides might be working through a
lytic mechanism rather than a cell-penetrating mechanism, mem-
brane permeabilization in the presence of peptide was tested using1
1.2
1.4
1.6
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2
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F/
F 0
time (min)
Fig. 4. Representative ﬂuorescence traces from membrane permeabilization experi-
ments using E. coli cells exposed to peptide (2 μM) in the presence of propidium iodide
(20 μg/mL). Fluorescence was monitored at 617 nm with excitation at 535 nm.
Table 4
The effect of proline-to-alanine mutations on the permeabilizing ability of DesHDAP1
and DesHDAP3. Propidium iodide, a membrane impermeable DNA intercalator, can
enter bacterial cells only after membrane disruption. Data is presented as the ratio of
propidium iodide ﬂuorescence at 617 nm 5 min after addition of 2 μM peptide to the
ﬂuorescence before peptide addition. Uncertainty is reported as standard deviation.
F5/F0
Wildtype Proline mutant
BF2 1.29±0.1 –
Magainin 1.52±0.2 –
DesHDAP1 1.12 ±0.06 1.06±0.05
DesHDAP3 1.13±0.08 1.57±0.4
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DesHDAPs caused minimal membrane permeabilization. However,
while DesHDAP1 P11A caused even less permeabilization than the
wildtype designed peptide, DesHDAP3 P13A caused membrane per-
meabilization at a level comparable to magainin, a known lytic pep-
tide [24]. Thus, it appears that the P13A mutation enhances the
antibacterial activity of DesHDAP3 by converting the peptide into a
much more effective membrane permeabilizing agent.
3.3. Relevance of DesHDAP data on the role of proline in antimicrobial
peptides
These results for DesHDAP1 and DesHDAP3 also provide more
general insight into the role played by proline in the membrane per-
meabilization of antimicrobial peptides. Several previous studies had
observed that adding a proline residue to an antimicrobial peptide
decreased its ability to permeabilize membranes [25–27]. Since pro-
line disrupts α-helical structures, it is tempting to interpret the de-
creased permeabilization in peptide variants containing proline as
being due to their decreased α-helical structure. However, our data
on designed HDAP proline mutants emphasize that increased perme-
abilization is not a direct effect of a longer α-helical structure, but in-
stead arises because of changes in amphipathic structure that can
occur when adding or removing a proline residue from a peptide
sequence. For example, the α-helicity of both DesHDAP1 and
DesHDAP3 increased in their respective proline to alanine mutations
(P11A and P13A). However, this mutation only increased perme-
abilization in DesHDAP3, while it actually decreased permeabilization
in DesHDAP1. A helical wheel representation highlights that
DesHDAP3 is very amphipathic if allowed to form a fully α-helical
structure, as seems to occur in DesHDAP3 P13A (Fig. 7). However,Fig. 5. Circular dichroism spectra of all peptides were taken in 50% triﬂuoroethanol: 50%
(gray). B. CD spectra of DesHDAP3 (black) and DesHDAP3 P13A (gray).DesHDAP1 would not be particularly amphipathic in its fully α-heli-
cal structure (Fig. 7), as would be promoted by its P11A mutation.
In fact, the DesHDAP1 P11A mutation likely forces some polar resi-
dues (e.g. Asp 3, Lys 6 and Thr 7) to lie on the more hydrophobic
face of the α-helix, making the peptide potentially less amphipathic
than in its original form that contains proline. These differences in
amphipathic nature, and not the extent of α-helicity, therefore dic-
tate the permeabilization of these peptides.
A similar effect was seen in studies by Oh et al. of cecropin–magai-
nin hybrid peptides [28]. In this study, a variant containing a central
proline residue increased membrane permeabilization despite induc-
ing a kink in the peptide that disrupted the helical structure in the
middle portion of the peptide. However, this kink allowed the peptide
to form two independent amphipathic helices rather than one longer
α-helix that would have no clear hydrophobic and hydrophilic faces.
Similarly, Xie et al. observed that BF2 variants containing either a pro-
line at residue 7 (P11A/G7P BF2) or no proline (P11A BF2) have very
similar membrane permeabilization abilities despite the increased α-
helicity that results from removing the proline [17]. Similar to our ob-
servations for DesHDAP1, this likely arises because extending the α-
helical structure of BF2 to the N-terminal side of residue 7 would
not effectively increase the amphipathic nature of the α-helix as the
N-terminal residues do not ﬁt well into the amphipathic pattern in
the rest of the peptide (Fig. 7). A molecular dynamics study of another
α-helical AMP, ovispirin, also suggests that the ability to form an am-
phipathic structure may correlate with membrane lytic behavior [29].
Our data on DesHDAP1 and DesHDAP3 also provide additional in-
sight into the role of proline in membrane translocation. In particular,
a proline hinge may be more likely to induce translocation in peptides
with less amphipathic character that do not readily form stable
membrane-disrupting structures, such as DesHDAP1 and BF2, by in-
creasing their ability to interact with lipids upon membrane entry.
In fact, deformations around proline that increase membrane interac-
tions have been observed in molecular dynamics simulations of BF2
interacting with lipid membranes [30]. The inclusion of a proline
hinge may be less effective in inducing translocation in peptides
that exhibit greater lytic potential, such as DesHDAP3, although addi-
tional examples of similar peptides with these properties would be
helpful to support this assertion.
4. Conclusions
The present study evaluated the mechanism of two recently
designed peptides, DesHDAP1 and DesHDAP3 [19]. In general, ourphosphate buffer solutions. A. CD spectra of DesHDAPs1 (black) and DesHDAP1 P11A
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Fig. 6. The antibacterial activity of the original DesHDAP1 (A), DesHDAP2 (B) and DesHDAP3 (C) peptides (solid bars) and their respective proline-to-alanine mutants (white bars)
were assessed with a radial diffusion assay. Error bars represent standard deviations.
875K.E. Pavia et al. / Biochimica et Biophysica Acta 1818 (2012) 869–876results suggest that DesHDAP1 shares a mechanism of action with
BF2 and are consistent with the hypothesis that both operate by
crossing bacterial membranes and interacting with intracellular tar-
gets like DNA. In addition to sharing a similar secondary structure
with BF2, DesHDAP1 readily translocates across cell membranes
without causing signiﬁcant membrane permeabilization. In contrast,
DesHDAP3's relatively weak bactericidal activity compared to BF2
and DesHDAP1 appears to result from it having both relatively poor
translocation and membrane permeabilization abilities. Interestingly,
a DesHDAP3 proline to alanine mutant makes that peptide much
more active against bacteria. Although that mutation does not en-
hance translocation, it does cause an increase in membrane perme-
abilization that appears to be primarily responsible for the peptide's
bactericidal potency. While it is clear that membrane perme-
abilization plays a more central role in the antibacterial activity of
DesHDAP3 than DesHDAP1, based on our data, we cannot determine
whether the wild type DesHDAP3 peptide's mechanism of action re-
lies solely on membrane permeabilization or on some combination
of weak membrane permeabilization and weak translocation.
Our results on DesHDAP1 and DesHDAP3 also provide insight into
the roles of proline residues in antimicrobial peptides and the role
of α-helicity as a predictor of antimicrobial peptide properties. In par-
ticular, our data emphasize the observation that the membrane per-
meabilization caused by antimicrobial peptides is not a direct effect
of the extent of α-helical structure, but instead arises because of the
amphipathic structure of a peptide. Similarly, our data also suggest
that the correlation of α-helicity with antimicrobial potency observed
for truncated BF2 mutants is not universally true for all HDAPsFig. 7. HDAP helical wheel depictions generated using the GROMACS suite [35].[17,22]. In spite of DesHDAP1's relatively low α-helical content com-
pared to that of the other HDAPs, it shows the greatest antimicrobial
potency. DesHDAP3 is a weaker antimicrobial agent and translocates
poorly, despite its signiﬁcant α-helical content. As with membrane
permeabilization, although α-helical character may be correlated
with antimicrobial activity in many cases, the overall activity of a pep-
tide results from a combination of its different properties that directly
impact microbial health, such as membrane permeabilization, mem-
brane translocation or the ability to interact with intracellular compo-
nents. These properties are all dictated by the overall physiochemical
properties of the peptide. While these properties are certainly related
to peptide structure, they are not necessarily dictated by the extent of
helical secondary structure, especially for peptides that do not follow
a straightforward amphipathic α-helical pattern.
Overall, the effectiveness of our designed HDAPs suggests that his-
tone derivatives could be a rich source of AMPs. However, our results
highlight that different histone fragments with antimicrobial activity
may function in different manners. Although many histone-related
proteins with antimicrobial activity have been isolated from natural
sources, their mechanism is only well characterized in a few cases.
In particular, the mechanism of BF2, which involves membrane trans-
location and nucleic acid interactions, has been fairly well established
[12,13,15,31]. More recently, researchers determined that parasin
kills bacteria through membrane lysis but does not readily translocate
into bacterial cells [32]. Since both parasin and BF2 are derived from
histone H2A, these studies have shown that antimicrobial fragments
of the same histone will not necessarily utilize an identical mecha-
nism of action. Strikingly, parasin was not derived from a DNAHydrophobic residues are shown in grey, and the proline hinge is outlined.
876 K.E. Pavia et al. / Biochimica et Biophysica Acta 1818 (2012) 869–876binding region of histone H2A, opening up the possibility that only
histone fragments derived from DNA binding regions of the protein
would function via a BF2-like mechanism. However, the data pre-
sented here show that at least some DNA-binding fragments from
histones, such as DesHDAP3, do not operate in a manner similar to
that of BF2. Ongoing work on other naturally occurring and synthetic
HDAPs as well as on the properties of full histones will be necessary to
obtain a systematic understanding of trends in HDAP activity. Multi-
ple studies have shown the utility of histones and histone fragments
not only as antimicrobial molecules but also as anti-cancer agents
[33] and in cellular transfection applications [34]. Thus, an increasing-
ly complete understanding of how histone derivatives function on
the molecular level will provide a foundation for future work in
which researchers attempt to rationally design and prepare histone-
derivatives with desired properties.
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